Showing results (11-20 of 36) with videos related to
Sort By:
Pageof 4
Plos One|February 23, 2012
Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activityMartin-Walter Welker, David Reichert, Simone Susser, et al.Virus Evolution|October 17, 2019
Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineageReilly Hostager, Manon Ragonnet-Cronin, Ben Murrell, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|October 30, 2015
Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevirBart Fevery, Simone Susser, Oliver Lenz, et al.Hepatology (Baltimore, Md.)|September 26, 2015
Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3Kai-Henrik Peiffer, Lisa Sommer, Simone Susser, et al.Antimicrobial Agents and Chemotherapy|February 26, 2015
Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevirSimone Susser, Mathieu Flinders, Henk W Reesink, et al.Genome Biology|January 25, 2008
Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virusChristoph Welsch, Francisco S Domingues, Simone Susser, et al.Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|April 10, 2018
Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patientsKai-Henrik Peiffer, Johannes Vermehren, Lisa Kuhnhenn, et al.Scandinavian Journal of Gastroenterology|August 6, 2011
HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2aChristian M Lange, Simone Susser, Eva Herrmann, et al.Antiviral Therapy|August 6, 2011
Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevirWolf Peter Hofmann, Tje Lin Chung, Carola Osbahr, et al.Journal of Hepatology|December 3, 2014
Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavageChristoph Welsch, Katrin Haselow, Jérôme Gouttenoire, et al.Pageof 4